Okinawa in Japan finds contaminants in Moderna Covid-19 vaccines: Report

The Okinawa vaccines are from different Moderna lots already suspended by the Japanese government due to reports of contamination, NHK said

Moderna
Black substances were spotted in syringes and a vial, while pink substances were found in a different syringe filled with vaccine at the Okinawa centre, NHK said
Reuters Tokyo
2 min read Last Updated : Aug 29 2021 | 8:12 AM IST
Contaminants were found in Moderna Inc's Covid-19 vaccines at a large-scale vaccination centre in Japan's Okinawa prefecture, suspending inoculations, public broadcaster NHK reported on Sunday.
 
The Okinawa vaccines are from different Moderna lots already suspended by the Japanese government due to reports of contamination, NHK said.
 
Black substances were spotted in syringes and a vial, while pink substances were found in a different syringe filled with vaccine at the Okinawa centre, NHK said.
 
Takeda Pharmaceutical Co, the domestic distributor of the Moderna vaccines, is expected to investigate the possibility of contamination during production and hold talks with Japan's health ministry, the broadcaster said.
 
Japan halted the use of 1.63 million Moderna doses, shipped to 863 vaccination centres nationwide, more than a week after Takeda received reports of contaminants in some vials.
 
The ministry said on Saturday that two people died after receiving Moderna's vaccine shots that were among lots later suspended following the discovery of contaminants.
 
Each had a shot from one of three manufacturing lots suspended on Thursday. The causes of death are being investigated.
Japan is battling its worst wave of infections, driven by the Delta variant, with new daily infections exceeding 25,000 this month for the first time.
 
The country has inoculated 54% of its population with at least one dose and fully vaccinated 43%, according to a Reuters vaccine tracker.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :JapanCoronavirus VaccineVaccinationVaccine

Next Story